Generic Name and Formulations:
Polyethylene glycol 3350 200g, sodium sulfate 15g, sodium chloride 5.38g, potassium chloride 2.03g, ascorbic acid 9.4g, sodium ascorbate 11.8g; per 2L of soln; pwd for reconstitution; contains phenylalanine 131mg/treatment; lemon-flavor.
Valeant Pharmaceuticals, Inc
Indications for MOVIPREP:
Bowel cleansing before colonoscopy.
No solid food from start of prep. No clear liquids at least 2hrs before colonoscopy. For both regimens start the evening before colonoscopy. Split-dose regimen: drink 240mL every 15 mins over 1hr until 1L consumed, follow with 480mL of clear liquid; in the AM (start ≥3.5hrs before colonoscopy), drink 2nd liter over 1hr, then drink 480mL of clear liquid at least 2hrs before colonoscopy; or, Evening-only regimen: start at least 3.5hrs before bedtime; drink 240mL every 15 mins over 1hr until 1L consumed, then drink 2nd liter 1.5hrs later over 1hr; in addition, drink 1L of clear liquid.
<18yrs: not established.
GI obstruction. Bowel perforation. Gastric retention. Ileus. Toxic colitis or megacolon.
Correct fluid/electrolyte abnormalities before use. History of prolonged QT, uncontrolled arrhythmias, recent MI, unstable angina, CHF, or cardiomyopathy: increased risk of arrhythmias; consider ECGs at pre-dose and post-colonoscopy. History or risk of seizures. Renal impairment; monitor baseline and post-colonoscopy electrolytes, creatinine, BUN. Inflammatory bowel disease. Rule out suspected GI obstruction/perforation before administering. Severe ulcerative colitis. Impaired gag reflex. Risk of regurgitation or aspiration. G6PD deficiency. Maintain adequate hydration. Pregnancy (Cat.C). Nursing mothers.
Caution with drugs that increase risk of fluid/electrolyte abnormalities, arrhythmias or QT prolongation. Drugs that may lower the seizure threshold (eg, tricyclic antidepressants), alcohol or benzodiazepine withdrawal, known or suspected hyponatremia: may increase risk of seizures. Concomitant diuretics, ACE inhibitors, ARBs, NSAIDs; may affect renal function. Concomitant stimulant laxatives: not recommended; may increase risk of colonic ulceration, ischemic or ulcerative colitis. Oral drugs administered within 1hr of start of MoviPrep may not be absorbed.
Malaise, nausea, vomiting, abdominal distension and pain (give slowly or discontinue if occurs), anal discomfort, thirst, sleep disorder, rigors, hunger, dizziness; rare: arrhythmias, seizures.
Carton—1 (disposable container w. 4 pouches)
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|